“Bimekizumab Durability of High-Level Clinical and Quality of Life Responses in Early Responders with Moderate to Severe Plaque Psoriasis: 4-Year Results from Four Phase 3 Trials”, J of Skin, vol. 10, no. 3, p. s773, May 2026, doi: 10.25251/h6t2hj68.